Clinical trials: Cryptogenic Ischemic Stroke
Embolic Stroke of Undetermined Source
Registry Study for the Observation of Patients With ESUS/Cryptogenic Stroke
Up to know, there is no clear diagnostic and therapeutic pathway for patients with embolic stroke of undetermined source (ESUS).
- Trial name
- Catch-up-ESUS (NCT03820375)
- Where
- Germany
- Volunteers
- 750 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Cryptogenic Stroke or TIA, Atrial Fibrillation
Detection of Occult Paroxysmal AF in Cryptogenic Stroke or TIA Patients Using an Implantable Loop Recorder and Correlation With Genetic Markers.
Atrial fibrillation (AF) is the significant risk factor of ischemic stroke with incidence about 20% of all ischemic strokes. The undiagnosed AF in cryptogenic stroke patients could be present but not revealed by rutinne ECG.
- Trial name
- NCT02216370
- Where
- Slovakia
- Volunteers
- 125 people
- Sponsor
- University Hospital, Martin
Patent Foramen Ovale, Cryptogenic Stroke
Long-term Outcomes After Percutaneous Patent Foramen Ovale Closure (Severance PFO Registry)
Patent foramen ovale (PFO) is a congenital interatrial communication present in about one quarter of the general population and is recognized as a major cause of cryptogenic stroke.
- Conditions
- Patent Foramen Ovale, Cryptogenic Stroke, Transient Ischemic Attack Due to Embolism, Atrial Fibrillation
- Trial name
- NCT07724171
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Yonsei University
Cerebrovascular Stroke, Atrial Fibrillation
Prediction and Detection of Occult Atrial Fibrillation in Patients After Acute Cryptogenic Stroke and TIA
PROACTIA is a prospective, event-driven observational study. It aims to propose a composite scoring system in order to evaluate the risk of paroxysmal atrial fibrillation (PAF) in patients after acute cryptogenic stroke and…
- Trial name
- PROACTIA (NCT02725944)
- Testing
- Implantation of ICRM
- Where
- Norway
- Volunteers
- 251 people
- Sponsor
- University Hospital, Akershus
Patent Foramen Ovale
Paradigm I Clinical Trial: Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism
The primary objective of this study is to demonstrate the safety of the PFX Closure System when utilized for patients with patent foramen ovale (PFO) suffering from cryptogenic stroke, transient ischemic attacks or paradoxical…
- Trial name
- NCT00196027
- Testing
- PFX Closure System
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cierra
Patent Foramen Ovale, Cryptogenic Stroke
Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure
Patent foramen ovale PFO closure has been shown to reduce the risk of stroke in patients with recurrent stroke. However, the majority of existing clinical studies in this field excluded patients over the age of 60 years.
- Conditions
- Patent Foramen Ovale, Cryptogenic Stroke, Older Patients, Medical Treatment
- Trial name
- STOP (NCT05907694)
- Testing
- Transcatheter PFO closure, Optimal medical treatment
- Where
- 2 sites in Canada
- Volunteers
- 714 people
- Sponsor
- Josep Rodes-Cabau
Stroke, Transient Ischemic Attack
GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients
The primary objective is to determine if patent foramen ovale (PFO) closure with the GORE® HELEX® Septal Occluder or GORE® CARDIOFORM Septal Occluder plus antiplatelet medical management is safe and effective and reduces the risk…
- Trial name
- REDUCE (NCT00738894)
- Testing
- Septal Occluder Device, Antiplatelet Medical Therapy
- Where
- 2 sites in United States, Denmark
- Volunteers
- 664 people
- Sponsor
- W.L.Gore & Associates
Atrial Fibrillation (AF)
CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke
Early detection of atrial fibrillation detected after stroke (AFDAS) is crucial for secondary stroke prevention, as initiating direct oral anticoagulants (DOACs) can reduce atrial fibrillation (AF)-related stroke risk by up to…
- Trial name
- CATCH-AF (NCT07899788)
- Testing
- CardioWatch 287-2 Group, Control Group
- Where
- Austria
- Volunteers
- 1,500 people
- Sponsor
- Medical University of Graz
Cardiac Arrythmias, Syncope
Confirm Rx™ Versus Reveal LINQ™ - Which is More Reliable in Data Transmission? A Randomized Clinical Study
This study will compare the reliability and timeliness in data transmission of the Abbott Confirm Rx™ loop recorder with the Medtronic Reveal LINQ™ loop recorder.
- Conditions
- Cardiac Arrythmias, Syncope, Atrial Fibrillation, Atrial Flutter
- Trial name
- NCT03720639
- Testing
- Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM
- Where
- 2 sites in United States
- Volunteers
- 209 people
- Sponsor
- Sparrow Clinical Research Institute
Stroke, Stroke, Ischemic
MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits
This is a multi-center, randomized, double-blind, placebo-controlled trial of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 high-dose twice a day, MLC1501…
- Conditions
- Stroke, Stroke, Ischemic, Strokes Thrombotic, Stroke Sequelae
- Trial name
- MAESTOSO (NCT05289947)
- Testing
- MLC1501
- Where
- 11 sites in Philippines, Singapore
- Volunteers
- 303 people
- Sponsor
- Moleac Pte Ltd.
Stroke
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
Objectives Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
- Trial name
- ARCADIA (NCT03192215)
- Testing
- Apixaban, Aspirin
- Where
- 177 sites in United States, Canada
- Volunteers
- 1,015 people
- Sponsor
- Columbia University
Patent Foramen Ovale, Closure; Foramen Ovale
Residual Shunt After Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke
Among consecutive 47 cryptogenic stroke patients who underwent PFO closure, a serial follow-up bubble contrast TEE at 3 and 9 months after the index procedure was completed in 38 patients (81%, 46±10 years, 19 men).
- Trial name
- NCT03416426
- Testing
- Amplatzer® PFO occluder or Gore® Septal Occluder
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Gachon University Gil Medical Center